BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 21129324)

  • 1. Factors influencing the effectiveness of glucagon for preventing hypoglycemia.
    Castle JR; Engle JM; El Youssef J; Massoud RG; Ward WK
    J Diabetes Sci Technol; 2010 Nov; 4(6):1305-10. PubMed ID: 21129324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy determinants of subcutaneous microdose glucagon during closed-loop control.
    Russell SJ; El-Khatib FH; Nathan DM; Damiano ER
    J Diabetes Sci Technol; 2010 Nov; 4(6):1288-304. PubMed ID: 21129323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies.
    Wilinska ME; Budiman ES; Taub MB; Elleri D; Allen JM; Acerini CL; Dunger DB; Hovorka R
    J Diabetes Sci Technol; 2009 Sep; 3(5):1109-20. PubMed ID: 20144424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: preliminary studies in Padova and Montpellier.
    Bruttomesso D; Farret A; Costa S; Marescotti MC; Vettore M; Avogaro A; Tiengo A; Dalla Man C; Place J; Facchinetti A; Guerra S; Magni L; De Nicolao G; Cobelli C; Renard E; Maran A
    J Diabetes Sci Technol; 2009 Sep; 3(5):1014-21. PubMed ID: 20144414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.
    Wilson LM; Jacobs PG; Ramsey KL; Resalat N; Reddy R; Branigan D; Leitschuh J; Gabo V; Guillot F; Senf B; El Youssef J; Steineck IIK; Tyler NS; Castle JR
    Diabetes Care; 2020 Nov; 43(11):2721-2729. PubMed ID: 32907828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience.
    Clarke WL; Anderson S; Breton M; Patek S; Kashmer L; Kovatchev B
    J Diabetes Sci Technol; 2009 Sep; 3(5):1031-8. PubMed ID: 20144416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes.
    Bakhtiani PA; El Youssef J; Duell AK; Branigan DL; Jacobs PG; Lasarev MR; Castle JR; Ward WK
    J Diabetes Complications; 2015; 29(1):93-8. PubMed ID: 25264232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
    Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
    Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated multivariable artificial pancreas control system.
    Turksoy K; Quinn LT; Littlejohn E; Cinar A
    J Diabetes Sci Technol; 2014 May; 8(3):498-507. PubMed ID: 24876613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bio-inspired glucose controller based on pancreatic β-cell physiology.
    Herrero P; Georgiou P; Oliver N; Johnston DG; Toumazou C
    J Diabetes Sci Technol; 2012 May; 6(3):606-16. PubMed ID: 22768892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results.
    Kovatchev B; Cobelli C; Renard E; Anderson S; Breton M; Patek S; Clarke W; Bruttomesso D; Maran A; Costa S; Avogaro A; Dalla Man C; Facchinetti A; Magni L; De Nicolao G; Place J; Farret A
    J Diabetes Sci Technol; 2010 Nov; 4(6):1374-81. PubMed ID: 21129332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.
    Ranjan A; Nørgaard K; Tetzschner R; Steineck IIK; Clausen TR; Holst JJ; Madsbad S; Schmidt S
    Diabetes Care; 2018 Apr; 41(4):797-806. PubMed ID: 29358493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
    Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.
    Wendt SL; Ranjan A; Møller JK; Schmidt S; Knudsen CB; Holst JJ; Madsbad S; Madsen H; Nørgaard K; Jørgensen JB
    J Diabetes Sci Technol; 2017 Nov; 11(6):1101-1111. PubMed ID: 28654314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bionic pancreas: novel perspectives on insulin replacement therapies.
    Denecke C
    Transplantation; 2015 Feb; 99(2):268-9. PubMed ID: 25651115
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of a bihormonal closed-loop system to control postexercise and postprandial glucose excursions.
    Van Bon AC; Jonker LD; Koebrugge R; Koops R; Hoekstra JB; DeVries JH
    J Diabetes Sci Technol; 2012 Sep; 6(5):1114-22. PubMed ID: 23063038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors.
    Castle JR; El Youssef J; Wilson LM; Reddy R; Resalat N; Branigan D; Ramsey K; Leitschuh J; Rajhbeharrysingh U; Senf B; Sugerman SM; Gabo V; Jacobs PG
    Diabetes Care; 2018 Jul; 41(7):1471-1477. PubMed ID: 29752345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of an automated artificial pancreas using zone-model predictive control and health monitoring system.
    Harvey RA; Dassau E; Bevier WC; Seborg DE; Jovanovič L; Doyle FJ; Zisser HC
    Diabetes Technol Ther; 2014 Jun; 16(6):348-57. PubMed ID: 24471561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.